USE OF MYCOPHENOLATE MOPHETYL IN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

The article reports a case of highly active SLE and lupusbnephritis in a 15 years old boy, who was treated with mycophenolate mophetyl the case was notable for high activity and aggressive course of the disease with rapid development of renal unsufficiency, polyorganic unsufficiency and antiphospholipid syndrome. Although the patient received an appropriate active therapy, including synchronized therapy (consisting of timebrelated plasmopherresis and infusions of cyclophosphamide and metyl prednisolone), glucocorticoides, preparations improving blood circulation (pentoxyphillin, dipiridamol, heparine), intravenous immunoglobulins, the disease activity control was unsufficient. The administration of mycophenolate mophetyl has led to diminuition of the disease activity, which was registered at the end of the second week of treatment, and finally has reached a level of clinical and laboratoty remission of the disease.Key words: systemic lupus erythematosus, mycophenolate mophetyl, children, treatment

NEW OPPORTUNITIES IN TREATMENT OF JUVENILE ANKYLOSING SPONDYLOARTHRITIS

Development of effective and safe methods of treatment of juvenile ankylosing spondyloarthritis is one of topical problems of modern rheumatology. At the same time, the number of antirheumatic drugs used for the treatment of this disease is limited. It is necessary to widen a range of immunosuppressive medications for inclusion of genetically engineered biological agents. The objective of performed open-labeled trial was effectiveness and safety of monoclonal antibodies to tumor necrotizing factor (TNF) _ — infliximab. The study included 107 patients with juvenile ankylosing spondyloarthritis. 58 children were treated with infliximab, and 49 — with sulfasalazine. Duration of treatment was 54 weeks. In the end of a study 42% of patients treated with infliximab had status of inactive disease, and only 2% of patients in sulfasalazine group had the same status.Key words: children, juvenile ankylosing spondyloarthritis, infliximab, sulfasalazine, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(2):23-31